Clinical trial
A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With…
NCT00046111 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00046111 |
|---|---|
| Title | A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors |
| Official title | A Study to Determine the Bioequivalence of an Oral Formulation of Topotecan Containing the Drug Substance Manufactured by New Process Relative to the Current Study Formulation of Topotecan in Patients With Advanced Solid Tumors |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lung Cancer, Small Cell, Solid Tumor Cancer |
| Intervention type | Drug |
| Interventions | topotecan |
| Enrollment | 1 |
| Start date | Sep 1, 2001 |
| Primary completion | Apr 1, 2004 |
| Completion | Apr 1, 2004 |
| First posted | Sep 23, 2002 |
| Last update posted | May 30, 2017 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: